Biota cuts costs to conserve cash horde
This article was originally published in Scrip
Executive Summary
Biota Pharmaceuticals, the company resulting from the merger between Nabi Biopharmaceuticals and Biota Holdings last November, has announced a 'revised corporate strategy' which, amongst other measures, involves a 30% reduction in its workforce 'over the next several quarters'.